EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PRA Health Sciences's enterprise value is $11,473 Mil.
PRA Health Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2021 was $445 Mil. Therefore, PRA Health Sciences's EV-to-EBITDA for today is 25.79.
The historical rank and industry rank for PRA Health Sciences's EV-to-EBITDA or its related term are showing as below:
PRAH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.08 Med: 18.76 Max: 34.24
Current: 26.04
During the past 9 years, the highest EV-to-EBITDA of PRA Health Sciences was 34.24. The lowest was 12.08. And the median was 18.76.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
PRA Health Sciences EV-to-EBITDA Historical Data
The historical data trend for PRA Health Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PRA Health Sciences's EV-to-EBITDA
For the Diagnostics & Research subindustry, PRA Health Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PRA Health Sciences's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, PRA Health Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PRA Health Sciences's EV-to-EBITDA falls into.
PRA Health Sciences's current Enterprise Value is $11,473 Mil.
PRA Health Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $445 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRA Health Sciences (NAS:PRAH) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
PRA Health Sciences's PE Ratio for today is calculated as:
PRA Health Sciences's share price for today is $165.21.
PRA Health Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.270.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of PRA Health Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
PRA Health Sciences (PRA Health Sciences) Business Description
PRA Health Sciences is a global contract research organization that provides drug development and clinical trial services to pharmaceutical and biotechnology firms. Its services run from early- to late-stage clinical trial outsourcing with varying levels of support, including one-off specialized staffing services to strategic partnerships where PRA handles nearly all aspects of the trial. In 2017, PRA acquired Symphony Health, a healthcare data and analytics provider. PRA's competitor, Icon, announced it will acquire PRA for $12 billion, which is scheduled to close in third-quarter 2021.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRAH has been successfully added to your 